Brain Boost: Billionaires and the Future of Thought

Elon Musk, known for his ventures in space travel, electric vehicles, artificial intelligence, and robotics, is now turning his attention to the human brain. Similarly, Sam Altman, head of OpenAI, the creator of the widely used ChatGPT, is also entering this field. Both, alongside other wealthy individuals, are investing in the potential of the human mind.

Their focus on brain-computer interfaces (BCIs) highlights not only the current medical advancements but also an emerging competition to control the direct neural connection to digital life. Sources interviewed by *Decrypt* suggest that billionaire involvement, while boosting the industry’s profile, could also create skewed priorities.

For these billionaires, BCIs extend beyond medical tools; they are seen as the potential next major platform, a key to managing the link between human thought and digital systems.

Controlling this interface could translate to controlling the future of computing. The significant investment in BCIs by influential figures underscores their belief that it’s a safeguard against AI dominance, a new control point in technology, and a potentially lucrative area for profit and influence.

Musk and Altman’s Strategic Moves

Musk established Neuralink in 2016 with the ambitious objective of integrating humans with machines, viewing it as essential for keeping up with advancements in artificial intelligence. The company recently secured $650 million in a Series E funding round, positioning it as a leader in the BCI space. Neuralink’s initial human trial participant, Noland Arbaugh, has demonstrated the ability to control a computer cursor and navigate the internet using only his thoughts.

While the results have varied, Neuralink has implanted devices in five patients and plans to expand trials to address speech impairments and restore vision. Musk consistently portrays BCIs as more than just medical devices, emphasizing their role as a protective measure for humanity in an AI-driven world.

Meanwhile, Altman has emerged as a co-founder of Merge Labs, a new company seeking to raise approximately $250 million with a potential valuation of $850 million. Initial reports suggest Merge Labs may explore non-invasive interfaces, offering an alternative approach to Neuralink’s implant-based technology.

For Altman, already leading a major AI company, this move implies that the future competition involves not only creating advanced AI models but also controlling the pathways that connect these models to human minds.

Other Notable Investments

The interest in BCIs extends beyond Musk and Altman. Bryan Johnson, a prominent figure in biohacking who made his wealth in the payments industry, invested $100 million in Kernel back in 2016. Johnson’s Kernel is focused on developing neurotech platforms to measure brain activity, positioning itself as an essential infrastructure provider rather than focusing on implant technology.

Neuralink’s investors also include Peter Thiel’s Founders Fund, signifying that prominent venture capitalists in Silicon Valley are preparing for a future where brain-computer interfaces become a fundamental layer of computing.

“Their involvement is definitely encouraging,” Tetiana Aleksandrova, CEO and co-founder of the neurotechnology startup Subsense, told *Decrypt*. “Billionaire investment in BCI brings visibility and funding that significantly boosts the entire industry. More investors are considering allocating resources to neurotechnology, leading to the creation of more companies and attracting engineers to this exciting field.”

However, Aleksandrova also cautioned that billionaire involvement has potential downsides.

“While their funding can speed up progress beyond what public funding typically allows, the pressure to achieve rapid results can lead to unrealistic promises that erode trust. In science, trust is as essential as funding,” she explained.

Andreas Melhede, co-founder of Elata Bioscience, a neuroscience-focused DAO, stated to *Decrypt* that although billionaire involvement drives interest and funding, it can also narrow the research focus.

“The priorities tend to reflect the specific vision of an individual or a tightly controlled corporate agenda, rather than the broader scientific community,” he stated. “This often leads to research being directed towards attention-grabbing ‘moonshot’ projects rather than crucial collaborative advancements that genuinely advance the field.”

Melhede agreed that the rhetoric from billionaires could both benefit and harm the industry by overshadowing less flashy, but important work. He emphasized the greater risk is the centralization of control over a resource as significant as the human brain.

“If one company controls the infrastructure, code, and data, they essentially hold the keys to an individual’s thoughts and intentions,” he explained. “This can hinder transparency and slow down independent validation and scientific progress. Access to BCI technology—and cognitive autonomy—becomes subject to the business decisions of a select few influential figures. That places too much risk in too few hands.”

The Gap Between Expectations and Reality

This tension defines the field. The grand vision presented by billionaires – controlling the neural interface and, consequently, the future – contrasts sharply with the current limitations: imprecise signals, delicate hardware, and systems that cannot truly “read thoughts” as often suggested.

However, such a breakthrough remains “conceivable at some point,” according to Gary Marcus, a cognitive scientist and professor *emeritus* of psychology and neural science at New York University, as stated to *Decrypt*. “Currently, our understanding of the neural code is insufficient. Of course, there are existing interventions that are highly beneficial for individuals who are paralyzed or have limited options.”

Companies such as Synchron and Inbrain are continuing their pilot studies. Inbrain’s graphene-based BCI platform has even received the FDA Breakthrough Device designation. However, these efforts are still in their early stages and far from being widely available for enhancement purposes.

What’s at Stake

The central question isn’t necessarily whether brain-computer interfaces will become widespread, but rather whose vision will shape their development and application. Musk views BCIs as a vital safeguard against existential threats. Altman sees them as strategic control points. Johnson and Thiel consider them long-term infrastructure investments.

For patients, this technology represents the opportunity to regain lost abilities. For billionaires, it’s about creating the next major human-machine interface – a future where the controller of the gateway may ultimately dictate how thoughts are transformed into data.